Physician profile
Gavin Ferguson
NPI 1265943252
$9,309.35
in general payments reported to CMS, 2019-2025
11 companies · $8,102 in 2025
The $8,102 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $412 · 2023: $205 · 2024: $470 · 2025: $8,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,400 · Travel and Lodging: $2,280 · Food and Beverage: $2,096.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,400.00 |
| Travel and Lodging | $2,280.41 |
| Food and Beverage | $2,096.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $6,394.58 | 2024-2025 | Epclusa |
| Abbvie INC. | $1,908.32 | 2025 | |
| Janssen Pharmaceuticals, INC | $280.29 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $239.13 | 2022-2024 | Ingrezza |
| Madrigal Pharmaceuticals | $150.00 | 2024 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $86.10 | 2022-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $66.90 | 2023-2024 | Uzedy, Austedo |
| Alkermes, INC. | $64.18 | 2022-2023 | Aristada, Lybalvi |
| Indivior INC. | $36.56 | 2022-2023 | Perseris |
| Idorsia Pharmaceuticals US INC | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.